Welcome to our dedicated page for Aileron Therapeutics news (Ticker: ALRN), a resource for investors and traders seeking the latest updates and insights on Aileron Therapeutics stock.
Aileron Therapeutics, Inc. (NASDAQ: ALRN) is a clinical-stage biopharmaceutical company pioneering the development of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications. Located in Boston, Massachusetts, Aileron is leading the front in peptide therapeutics, focusing on innovative treatments for severe diseases.
The company’s flagship product is ALRN-6924, a unique chemoprotective agent designed to reactivate p53-mediated tumor suppression. Currently under multiple clinical trials, ALRN-6924 targets both MDMX and MDM2 proteins, pivotal in restoring the p53 function, often referred to as the “guardian of the genome,” due to its significant role in cancer prevention.
Another promising candidate is LTI-03, a novel Caveolin-1-related peptide in development for treating idiopathic pulmonary fibrosis (IPF). It is in a Phase 1b clinical trial, with results expected in the second quarter of 2024. Additionally, LTI-01 is a proenzyme under clinical evaluation for treating loculated pleural effusions, having completed Phase 1b and Phase 2a trials.
In the wake of challenging results from a Phase 1b breast cancer trial of ALRN-6924, leading to its termination, Aileron has been exploring strategic alternatives to maximize shareholder value. Recently, the company acquired Lung Therapeutics, Inc., integrating a pipeline of therapies targeting orphan pulmonary diseases.
The company remains well-funded, following an $18 million acquisition-financing round, bolstering its financial stability to propel ongoing clinical trials and corporate initiatives. As Aileron transitions under new leadership, with Dr. Brian Windsor as CEO, it continues to prioritize advancing its therapeutic candidates toward commercialization.
Visit aileronrx.com for more information about their groundbreaking research and future developments.
Aileron Therapeutics (NASDAQ:ALRN) announced that its CEO, Manuel Aivado, will participate in a fireside chat at the William Blair Biotech Focus Conference 2021 on July 15, 2021, at 3:00 p.m. ET. Virtual 1x1 meetings will be held from July 14-15. A webcast of the chat will be available on Aileron’s website, with a replay archived for 30 days. Aileron focuses on improving chemotherapy experiences for cancer patients, specifically targeting those with p53-mutated cancers using its lead product, ALRN-6924, which aims to reduce chemotherapy-related side effects.
Aileron Therapeutics (Nasdaq: ALRN) has initiated a Phase 1b trial for ALRN-6924, targeting 60 patients with advanced p53-mutated non-small cell lung cancer (NSCLC) undergoing chemotherapy. This randomized, double-blind, placebo-controlled trial will assess treatment cycles free of severe toxicities and the impact on patients' quality of life. The first interim safety data is expected by late 2021, with final results anticipated in mid-2022. Aileron aims to utilize ALRN-6924 as a chemoprotective agent to selectively shield healthy cells while allowing the chemotherapy to target cancer cells, addressing a significant need for cancer patients.
Aileron Therapeutics (NASDAQ:ALRN) announced its inclusion in the Russell Microcap® Index, effective June 28, 2021. This membership lasts for one year and grants automatic inclusion in relevant growth and value style indexes, which can potentially broaden its investor base. Aileron focuses on chemoprotection oncology, developing ALRN-6924, a dual inhibitor aimed at protecting healthy cells during chemotherapy. With nearly 1 million p53-mutated cancer diagnoses annually in the U.S., the company addresses a significant medical need.
Aileron Therapeutics (NASDAQ:ALRN) will host a fireside chat on May 26, 2021, at 11:00 am ET, focusing on the chemoprotection of cancer patients from chemotherapy-induced toxicities. Moderated by Soumit Roy, Ph.D., the event will feature hematologist Alan List, M.D., and geriatric oncologist Lodovico Balducci, M.D. They will discuss the need for chemoprotection and its potential to improve patients' quality of life. Aileron's ALRN-6924, a dual MDM2/MDMX inhibitor, is in development to provide selective chemoprotection for patients with p53-mutated cancers, impacting nearly 50% of cancer patients.
Aileron Therapeutics (NASDAQ:ALRN) announced key developments regarding ALRN-6924, targeting p53-mutated non-small cell lung cancer (NSCLC). The company plans to initiate a Phase 1b trial in Q2 2021, with interim results expected by year-end. Aileron aims to enhance chemotherapy tolerability through selective chemoprotection, potentially improving patients' quality of life. Financially, Aileron raised $55.7 million in Q1 2021, enhancing its cash position to $63.4 million. Despite a net loss of $7.0 million, the company expects this funding to extend operations into late 2023.
Aileron Therapeutics (NASDAQ:ALRN) reported significant progress in 2020, focusing on chemoprotection for cancer patients with p53 mutations. The company achieved clinical proof-of-concept in its Phase 1b trial for ALRN-6924 in small cell lung cancer (SCLC) and is set to initiate a new Phase 1b trial for ALRN-6924 in advanced non-small cell lung cancer (NSCLC) in Q2 2021. The company raised $55.7 million in early 2021, with a cash position of $13.8 million as of December 31, 2020, expected to fund operations into late 2023, indicating strong financial support for ongoing trials.
Aileron Therapeutics (NASDAQ:ALRN) announced that CEO Manuel Aivado will present at the 2021 H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021. The presentation will highlight the Phase 1b trial of ALRN-6924 for advanced p53-mutated non-small cell lung cancer, set to begin in Q2 2021. Aileron's innovative approach aims to protect healthy cells from chemotherapy without hindering its efficacy against cancer cells, potentially enhancing patient quality of life. A webcast will be available for replay on Aileron’s website after the event.
Aileron Therapeutics (Nasdaq: ALRN) plans to expand enrollment in its Phase 1b clinical trial of ALRN-6924, targeting 60 patients with advanced p53-mutated non-small cell lung cancer (NSCLC), up from 40. This trial aims to determine the efficacy of ALRN-6924 in reducing chemotherapy-induced side effects while preserving treatment effectiveness. Initial data is expected by late 2021, with full results by mid-2022. The recent FDA approval of a chemoprotective agent paves the way for ALRN-6924, a biomarker-based approach designed to protect healthy cells during chemotherapy.
Aileron Therapeutics (Nasdaq: ALRN) announced a registered direct offering of 32,630,983 shares of common stock at $1.10 each, with an expected gross proceeds of $35.9 million. The offering is anticipated to close around January 8, 2021, subject to customary conditions. Funds from this offering will be directed towards the clinical development of ALRN-6924, aimed at providing chemoprotection for patients undergoing chemotherapy, along with general working capital. The shares are offered under a shelf registration statement with the SEC.
Aileron Therapeutics (NASDAQ:ALRN) outlined its 2021 strategic priorities, focusing on advancing chemoprotection for patients with p53-mutant cancers. Key milestones include initiating a Phase 1b trial for ALRN-6924 in advanced non-small cell lung cancer (NSCLC) in Q2 2021, with initial results expected in Q4 2021. The company aims to protect healthy cells from chemotherapy side effects while allowing effective cancer treatment. Aileron anticipates enrolling about 40 patients in the trial and continuing to report data from ongoing studies in small cell lung cancer (SCLC).
FAQ
What is the current stock price of Aileron Therapeutics (ALRN)?
What is the market cap of Aileron Therapeutics (ALRN)?
What does Aileron Therapeutics specialize in?
What is ALRN-6924?
What recent strategic move did Aileron make?
Who is the new CEO of Aileron Therapeutics?
What is LTI-03, and its significance?
What are the financial prospects for Aileron?
What was the outcome of the ALRN-6924 breast cancer trial?
How is Aileron's intellectual property portfolio?
What are LTI-01's clinical achievements?
Where can one find more information about Aileron Therapeutics?
